Download Namenda (Alzheimer's disease) - Analysis and Forecasts to 2022 Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/2152219/
Namenda (Alzheimer's disease) - Analysis and Forecasts to 2022
Description:
Namenda (Alzheimer’s disease) – Analysis and Forecasts to 2022
Summary
GlobalData’s pharmaceuticals report, “Namenda (Alzheimer’s disease) – Analysis and Forecasts to 2022”
provides Namenda global sales estimates. In addition, it covers detailed clinical assessment of the drug,
factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast
period (2002-2022). The report also includes information on Alzheimer's disease market. This report is built
using data and information sourced from GlobalData’s proprietary databases, primary and secondary
research using Company’s corporate website, SEC filings, investor presentations and featured press
releases, both from company and industry-specific third party sources, put together with in-house analysis,
by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Namenda including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Namenda including efficacy, safety, pricing, competition and other details which
influence its sales potential
- Global sales forecast for 2002-2022 for Namenda
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales
potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets
Keywords
Namenda, memantine, Ebixa, Axura, Memary, Lundbeck, Merz, Daiichi Sankyo, Alzheimer’s disease,
dementia, N-methyl-D-asparatate antagonist
Contents:
1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Alzheimer’s disease
2.2 Symptoms
2.3 Alzheimer’s disease Market
2.4 Epidemiology
2.5 Etiology
2.5.1 Age
2.5.2 Family History
2.5.3 Genetics
2.6 Economic Impact of Alzheimer’s disease
2.7 GlobalData Report Guidance
3 Alzheimer’s disease: Market Characterization
3.1 Alzheimer’s disease Market
3.2 Alzheimer’s disease Market Forecasts and CAGR
3.3 Drivers and Barriers of Alzheimer’s disease Therapeutics Market
3.3.1 Ageing Population
3.3.2 Patent Expiries
3.3.3 New Product Launches
3.3.4 High Unmet Need
4 Classification of Alzheimer’s disease
4.1 Stage 1 (Mild)
4.2 Stage 2 (Moderate)
4.3 Stage 3 (Severe)
5 Treatment for Alzheimer’s disease
5.1 Cognitive Symptoms
5.1.1 Cholinesterase Inhibitors (ChEIs)
5.1.2 NMDA antagonists
5.1.3 Other Pharmacotherapeutic Agents
5.2 Behavioural Symptoms and Mood Disorders
5.2.1 Non-pharmacological Approaches
5.2.2 Prescription Medicines
5.3 Next-generation Drugs
5.3.1 Disease Modifying Agents
5.3.2 Tau-directed Therapies
5.3.3 Other Therapies
6 Namenda
6.1 Introduction
6.2 Mechanism of Action
6.3 Clinical Studies
6.4 Approval History of Namenda
6.5 Factors Affecting Sales of Namenda
6.5.1 First and Only NMDA receptor antagonist
6.5.2 Low Competition
6.5.3 Availability in Multiple Formulations
6.5.4 High Safety
6.5.5 Unmet Need
6.6 Drug Evaluation
6.6.1 Drug Risk Benefit Score
6.6.2 Intensity of Competition
6.7 Sales Estimates
6.7.1 Target Patient Pool for Namenda
6.7.2 Dosing
6.7.3 Market Penetration
6.7.4 Annual Cost of Therapy
6.7.5 Global Sales Projections of Namenda
7 Alzheimer’s Disease Market: Appendix
7.1 Market Definitions
7.2 List of Abberiviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Number of Patients Approved to Take the Drug
7.3.5 Net Penetration of Drug
7.3.6 Net Annual Dosing
7.3.7 Annual Cost of Therapy
7.4 Drug Sales Estimates Model
7.5 Contact Us
7.6 Disclaimer
7.7 Sources
1.1 List of Tables
Table 1: Alzheimer’s disease, World, Major Pipeline Products in Phase III
Table 2: Mild Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms
Table 3: Moderate Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms
Table 4: Severe Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms
Table 5: Non-pharmacological Approaches for Behavioural Symptoms and Mood Disorders
Table 6: Experimental Disease Modifying Drugs in Phase III for Alzheimer’s disease
Table 7: Approval History of Memantine HCl
Table 8: Drug Risk Benefit Score of Namenda
Table 9: Average Annual Cost of therapy of Namenda, 2011
Table 10: Namenda, Alzheimer’s disease, Global, Sales Estimates ($m) , 2002-2022
Table 11: Namenda, Alzheimer’s disease, The US, Sales Estimates ($m) , 2004-2022
Table 12: Namenda, Alzheimer’s disease, The UK, Sales Estimates ($m) , 2003-2022
Table 13: Namenda, Alzheimer’s disease, France, Sales Estimates ($m) , 2003-2022
Table 14: Namenda, Alzheimer’s disease, Germany, Sales Estimates ($m) , 2002-2022
Table 15: Namenda, Alzheimer’s disease, Italy, Sales Estimates ($m) , 2002-2022
Table 16: Namenda, Alzheimer’s disease, Spain, Sales Estimates ($m) , 2002-2022
Table 17: Namenda, Alzheimer’s disease, Japan, Sales Estimates ($m) , 2011-2022
1.2 List of Figures
Figure 1: Brain Affected by Alzheimer’s disease
Figure 2: Estimated Lifetime Risks for Alzheimer’s by Age and Sex, The US
Figure 3: Estimated Number of Cases of Alzheimer’s disease (million), The US
Figure 4: Changes in Selected Causes of Death, The US, 2000-2008
Figure 5: Alzheimer’s disease, Global, Market Size Forecasts ($bn), 2011–2022
Figure 6: Drug Model Diagram of Namenda
Figure 7: Namenda, Alzheimer’s disease, Global, Sales Forecasts ($m), 2002–2022
Figure 8: Namenda, Alzheimer’s disease, The US, Sales Forecasts ($m), 2004–2022
Figure 9: Namenda, Alzheimer’s disease, The UK, Sales Forecasts ($m), 2003–2022
Figure 10: Namenda, Alzheimer’s disease, France, Sales Forecasts ($m), 2003–2022
Figure 11: Namenda, Alzheimer’s disease, Germany, Sales Forecasts ($m), 2002–2022
Figure 12: Namenda, Alzheimer’s disease, Italy, Sales Forecasts ($m), 2004–2022
Figure 13: Namenda, Alzheimer’s disease, Spain, Sales Forecasts ($m), 2002–2022
Figure 14: Namenda, Alzheimer’s disease, Japan, Sales Forecasts ($m), 2011–2022
Figure 15: Namenda, Global, Sales Distribution, 2014
Figure 16: Patients Approved for the Drug
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2152219/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Namenda (Alzheimer's disease) - Analysis and Forecasts to 2022
Web Address:
http://www.researchandmarkets.com/reports/2152219/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Site License:
USD 4000
Electronic (PDF) Single User:
USD 2000
Electronic (PDF) Enterprisewide:
USD 6000
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World